Lilly's LY2140023 differs from established antipsychotic drugs in that it targets glutamate rather than dopamine or serotonin receptors. There is a substantial body of evidence to suggest that glutamate, a neurotransmitter, may also be involved in the pathophysiology of schizophrenia.